Literature DB >> 29745347

Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents.

Kam L Hon1, Alexander K C Leung2, Alcy R Torres3.   

Abstract

BACKGROUND: New-Onset Refractory Status Epilepticus (NORSE) refers to a clinical presentation in a patient without active epilepsy or other existing relevant neurological disorder, with new onset of refractory status epilepticus in the absence of a clear acute or active structural, metabolic, or toxic cause. Febrile Infection-Related Epilepsy Syndrome (FIRES) is a subset of NORSE that requires a febrile infection between 24 hours and 2 weeks prior to the onset of refractory status epilepticus, with or without fever at the onset of status epilepticus, and with no restriction to the age of the patient. The literature on FIRES is scarce.
OBJECTIVE: This article reviews the pathophysiology, clinical features, and various treatment modalities in the treatment of FIRES.
METHODS: A Medline/Pubmed search was conducted using Clinical Queries with the key terms "Febrile Infection-Related Epilepsy Syndrome", "FIRES", "New-Onset Refractory Status Epilepticus" and "NORSE". The search strategy included meta-analyses, randomized controlled trials, clinical trials, reviews and pertinent references. Patents were searched using the key term "FIRES", "NORSE" and "Febrile Epilepsy Syndrome" from www.google.com/patents, www.uspto.gov, and www.freepatentsonline.com.
RESULTS: FIRES almost invariably begins with a mild nonspecific febrile illness in an otherwise healthy individual. Twenty-four hours to two weeks later, seizures begin and quickly become very frequent and worsen, becoming status epilepticus. Seizures can be simple motor, complex partial or secondary generalized. The exact etiology is not known. It is possible that the syndrome is caused by an inflammatory or autoimmune mechanism. Seizures in FIRES are notoriously very difficult to treat. Treatment modalities include, among others, various antiepileptic drugs, ketogenic diet, intravenous corticosteroids, intravenous immunoglobulin, and burst-suppression coma. The outcome is poor; most children are left with significant cognitive disability and refractory epilepsy. Recent patents for the management of FIRES are discussed.
CONCLUSION: FIRES is a rare epilepsy syndrome of unclear etiology in which children, usually of school age, suddenly develop very frequent seizures after a mild febrile illness. Seizures in FIRES are typically difficult to treat. The prognosis is poor. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Antiepileptic drugs; FIRES; NORSE; corticosteroids; fever; immunoglobulin; ketogenic diet; new-onset refractory status epilepticus; seizures.

Mesh:

Substances:

Year:  2018        PMID: 29745347     DOI: 10.2174/1872213X12666180508122450

Source DB:  PubMed          Journal:  Recent Pat Inflamm Allergy Drug Discov        ISSN: 1872-213X


  9 in total

Review 1.  Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Authors:  Wolfgang Löscher; Charles L Howe
Journal:  Front Mol Neurosci       Date:  2022-05-09       Impact factor: 6.261

2.  A case of febrile infection-related epilepsy syndrome (FIRES) in young adult: still a diagnostic and therapeutic challenge.

Authors:  Roberto Acampora; Pablo Quiroga Subirana; Luana Durante; Rossella Tonziello; Giuseppina Aversano; Maria Lieto; Patrizia Ripa; Maria Pia Mazzaferro
Journal:  Neurol Sci       Date:  2022-05-04       Impact factor: 3.830

3.  Protecting the blossoming brain - Neurocritical care in children.

Authors:  Sophia Julia Häfner
Journal:  Biomed J       Date:  2020-06-14       Impact factor: 4.910

4.  Sevoflurane as bridge therapy for plasma exchange and Anakinra in febrile infection-related epilepsy syndrome.

Authors:  Manuela L'Erario; Rosa Maria Roperto; Anna Rosati
Journal:  Epilepsia Open       Date:  2021-10-20

5.  Neuroimaging and neurological outcome of children with acute encephalitis.

Authors:  Heidi M Pöyhönen; Mikko J Nyman; Ville T Peltola; Eliisa S Löyttyniemi; Tuire T Lähdesmäki
Journal:  Dev Med Child Neurol       Date:  2022-05-08       Impact factor: 4.864

Review 6.  Vasculitis, Autoimmunity, and Cytokines: How the Immune System Can Harm the Brain.

Authors:  Alessandra Tesser; Alessia Pin; Elisabetta Mencaroni; Virginia Gulino; Alberto Tommasini
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

7.  An atypical case of febrile infection-related epilepsy syndrome following acute encephalitis: impact of physiotherapy in regaining locomotor abilities in a patient with neuroregression.

Authors:  Chanan Goyal; Waqar M Naqvi; Arti Sahu
Journal:  Pan Afr Med J       Date:  2020-06-17

Review 8.  Febrile seizures: an overview.

Authors:  Alexander Kc Leung; Kam Lun Hon; Theresa Nh Leung
Journal:  Drugs Context       Date:  2018-07-16

Review 9.  The off-label use of anakinra in pediatric systemic autoinflammatory diseases.

Authors:  Valerio Maniscalco; Sarah Abu-Rumeileh; Maria Vincenza Mastrolia; Edoardo Marrani; Ilaria Maccora; Ilaria Pagnini; Gabriele Simonini
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-16       Impact factor: 5.346

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.